ストックスクリーナーアプリを入手
477.32
2.88%
-14.15
アフターアワーズ：
476.59
-0.73
-0.15%
前日終値:
$491.47
開ける：
$489.46
24時間の取引高:
1.72M
Relative Volume:
1.19
時価総額：
$121.24B
収益：
$12.07B
当期純損益:
$3.95B
株価収益率:
31.13
EPS:
15.3349
ネットキャッシュフロー:
$3.19B
1週間 パフォーマンス:
+2.99%
1か月 パフォーマンス:
+8.15%
6か月 パフォーマンス:
+21.52%
1年 パフォーマンス:
+3.99%
1日の値動き範囲:
$473.45
$494.05
1週間の範囲:
$454.40
$503.88
52週間の値動き範囲:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Narrow-Moat Vertex's Strong CF Sales Drive Growth as Non-CF Portfolio Starts to Gain Traction - Morningstar
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - Business Wire
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Canaccord G - GuruFocus
Vertex Pharmaceuticals (VRTX) Sees Analyst Rating Maintained wit - GuruFocus
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - Yahoo Finance
HC Wainwright & Co. Raises Vertex Pharmaceuticals (VRTX) Price Target | VRTX Stock News - GuruFocus
Vanguard Group Inc. Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
NEOS Investment Management LLC Purchases 37,296 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $60.39 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Public Sector Pension Investment Board Has $8.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Top-Rated Stocks: Vertex Pharmaceuticals Sees Composite Rating Climb To 96 - Investor's Business Daily
Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Zions Bancorporation National Association UT Buys 9,452 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by State of New Jersey Common Pension Fund D - MarketBeat
Cibc World Market Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 6.93% Upside Potential - DirectorsTalk Interviews
Vertex’s Journavx Surpasses Half a Million Prescriptions Amid Biopharma Sector Developments - geneonline.com
1 reason I'd buy Vertex Pharmaceuticals stock and never sell - MSN
Promising Biotech Stocks To Add to Your WatchlistFebruary 15th - MarketBeat
Shell Asset Management Co. Sells 10,515 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Prospera Financial Services Inc Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Aberdeen Group plc - MarketBeat
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story - Yahoo! Finance Canada
Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Ins - GuruFocus
Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus
Vertex veers upwards on impressive results - The Pharma Letter
Vertex Pharmaceuticals Signals Confident Growth Beyond CF - TipRanks
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know - Yahoo Finance
Vertex’s CRISPR therapy rebounds in latest earnings - BioPharma Dive
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase - Finviz
Vertex Pharmaceuticals (VRTX): Scotiabank Raises Price Target to $558 | VRTX Stock News - GuruFocus
RBC Capital Lowers Vertex Pharmaceuticals' (VRTX) Price Target | - GuruFocus
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform - GuruFocus
Vertex Pharmaceuticals (VRTX) Analyst Maintains Rating and Raises Price Target | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says - marketscreener.com
Top Biotech Stocks To ConsiderFebruary 13th - MarketBeat
Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year - Fierce Pharma
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Topline Grows 10% - FXDailyReport.Com
Vertex Prepares Povetacicept For APRIL/BAFF Battle - Citeline News & Insights
Agree To Purchase Vertex Pharmaceuticals At $320, Earn 4.4% Using Options - Nasdaq
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp - BioSpace
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News - GuruFocus
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Insider Monkey
AI for investors - MLQ.ai
Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating - marketscreener.com
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
2.63%
大文字化:
|
ボリューム (24 時間):